-
The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug
Thursday, January 21, 2016 - 12:23pm | 490Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) saw a marked decline this week after Food and Drug Administration scientists said studies examining the effects of the firm's latest muscular dystrophy drug were inconsistent. The FDA's review of Sarepta's drug followed a similar dismissal of...
-
Oppenheimer On Upcoming BioMarin Panel: Efficacy Concerns Circulate
Monday, November 23, 2015 - 3:30pm | 416Read More...Last Friday, the FDA released briefing documents for a BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) meeting regarding drisapersen (Kyndrisa) scheduled to take place on Tuesday; the documents focused on efficacy concerns and dystrophin data. In a report issued Friday, Oppenheimer analysts assured...
-
Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling
Friday, November 20, 2015 - 11:19am | 502Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) gained more than 30 percent Friday morning, while shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) lost more than 6 percent. The Wall Street Journal reported that BioMarin faces an FDA advisory committee next week to vote for approval or...
-
What's Causing The Rally In BioMarin? CEO Answers
Monday, March 23, 2015 - 2:47pm | 339Read More...Shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) have witnessed a spectacular rise in the last year, up by more than 67 percent. What's causing this rally? Jean-Jacques Bienaime, BioMarin Pharmaceuticals CEO, was on CNBC Monday to answer that question and to discuss the new drugs that...
